Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Información del proyecto

ImmuneHunter

Identificador del acuerdo de subvención: 791323

DOI

10.3030/791323

Proyecto cerrado

Fecha de la firma de la CE 31 Octubre 2017

Fecha de inicio 1 Noviembre 2017

Fecha de finalización 30 Abril 2018

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

PROTOBIOS OU
Estonia

Objetivo

Chronic diseases (cancer, heart and mind diseases) are the leading causes of illness and death. By 2020 their contribution is expected to rise to 73% of all deaths (of which nearly half as premature). To radically reduce the related healthcare spending and contribute to healthy ageing, it is important to diagnose these diseases as early and accurately as possible by analyzing biomarkers. However, the current analytical platforms have been unable to handle the huge amounts of data that need to be analysed for the discovery of new biomarkers, and as a result: (1) only a small number of new biomarkers have been discovered and (2) current routine diagnostic tests are able to provide only a very restricted overview of patient’s health status.

Protobios applies a ground-breaking high-throughput antibody repertoire characterization technology Mimotope Variation Analysis (MVA) to discover new biomarkers, develop novel multiplexed diagnostics, and empower the discovery and development of therapeutics and vaccines. Compared to competing technologies, MVA is superior because (1) it allows to detect and distinguish many different disease signatures simultaneously and (2) the scalability and associated low cost of the MVA process make it applicable for frequent analysis, providing the additional advantage of establishing a robust health assessment tool.

We have used MVA technology to provide clinical diagnostics' development services in a pilot format to a limited number of biotech companies and research institutions. We have witnessed growing demand and signed six-figure contracts for 2018.

The key component of MVA is a sophisticated bioinformatics platform that enables molecular profiling of the immune response at an unprecedented resolution and accuracy. For full-scale market entry, we need to scale up the technical capability of the ICT platform so that the MVA service capacity grows by at least 100 times (corresponding to annual revenues of €20-25 million).

Ámbito científico (EuroSciVoc)

• ciencias médicas y de la salud › ciencias de la salud › salud pública y medio ambiental
• ciencias médicas y de la salud › medicina básica › inmunología
• ciencias médicas y de la salud › medicina básica › farmacología y farmacia › medicamento › vacuna
• ciencias médicas y de la salud › medicina clínica › oncología

Programa(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being PROGRAMA PRINCIPAL
  
• H2020-EU.3.1.4. - Active ageing and self-management of health
  
• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
  
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
  
• H2020-EU.3.1.6. - Health care provision and integrated care
  

Tema(s)

• SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
  

Régimen de financiación

SME-1 - SME instrument phase 1

Convocatoria de propuestas

H2020-SMEInst-2016-2017

Coordinador

PROTOBIOS OU

• Aportación neta de la UEn: € 50 000,00
• Dirección: MAEALUSE 4 ; 12618 Tallinn ; Estonia
• Pyme Sí:
  Región
  Eesti › Eesti › Põhja-Eesti
• Región: Eesti › Eesti › Põhja-Eesti
• Tipo de actividad: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coste total: € 71 429,00